The Psychedelic-Informed Care & Referrals Primer for Practitioners
A Beyond Consulting Resource
*This article and associated resources are not medical or legal advice.
What psychedelic-informed care actually means
Psychedelic-informed care does not require you to administer psychedelic medicines, endorse their use, or refer every curious patient down a treatment pathway. It means you can respond responsibly when the subject enters the room, because it will, whether or not you invited it in.
Here are the practical and legal considerations to know about psychedelic-informed care and referrals.
Basic mechanism and risk literacy. You don't need pharmacology-course depth, but you should know, at minimum, how the major categories differ. Serotonergic psychedelics, aka classic psychedelics, such as psilocybin and LSD act primarily through 5-HT2A receptor agonism. Ketamine works through NMDA receptor antagonism, a fundamentally different mechanism with its own risk profile, including dissociation, bladder toxicity with chronic heavy use, and blood pressure considerations. But will provide a fast-acting and safe solution for treatment resistant depression or MDD that is not responsive to the serotonin class of anti-depressants, when used in a controlled environment with trained professionals.
MDMA is neither–pharmacologically closer to an entactogen with distinct cardiovascular and serotonergic risks (MAOIs, notably), and known to be incredibly effective and supportive for PTSD. Conflating these three categories, which happens constantly in casual patient conversation, is the first thing to correct.
Medication and condition interactions. SSRIs and SNRIs can blunt the subjective effects of classic (serotonergic) psychedelics and, in some combinations, raise serotonin syndrome risk. Lithium in particular carries documented case reports of seizure with psychedelic use and is generally considered a contraindication. A personal or family history of psychosis or certain bipolar presentations warrants real caution, not a blanket refusal, but a serious conversation grounded in the specific patient in front of you.
Recognizing when harm-reduction counseling is the right move. Not every patient asking about psychedelics is asking for your permission or your referral. Some are going to do this regardless of what you say, whether through a legal state program, a retreat, or an underground guide. Refusing to engage doesn't protect the patient; it just removes you from the conversation at the moment they most need accurate information.
Careful documentation. What a patient discloses about psychedelic use is clinically relevant and belongs in the chart, framed the way you'd frame any other substance use disclosure: factually, without judgment, with attention to how it might interact with the rest of their care.
Knowing when and how to refer. This means having an actual referral pathway, not a vague sense that someone out there does this work. A patient who leaves your office with nowhere to go didn't get informed care. Here is the part most clinicians find disorienting: there is no single legal status for psychedelics. There are several, layered and inconsistent, and understanding the layering matters more than memorizing any one state's statute.
Ketamine occupies a unique position. It is FDA-approved for anesthesia and, as esketamine (Spravato nasal spray by J&J), for treatment-resistant depression, which means off-label ketamine use for depression, anxiety, and other conditions is legal, common, and practiced widely in outpatient settings. This is the one psychedelic (or psychedelic-adjacent) medicine most clinicians can prescribe or refer for without navigating a separate regulatory framework.
*Spravato is offered in two fixed doses via nasal spray and is self-administered in a regulated, approved clinical setting. Although it contains esketamine, its fixed dosing generally produces a lighter experience than what may be achieved with injectable ketamine. This is why we might refer to it as “psychedelic-adjacent”.
*Injectable ketamine, administered by intramuscular injection or intravenous (IV) infusion, allows for greater dosing flexibility. Doses may range from approximately 0.5 mg/kg to 1.5 mg/kg, depending on the clinical context and route of administration, while avoiding excessive sedation so that patients can remain engaged with and recall the experience. This flexibility allows treatment to be tailored from lighter, more subtle effects to deeper psychedelic experiences, including dissociative states. When administered skillfully, safely, and within a psychedelic-therapy-informed framework, these deeper experiences may also have therapeutic value.
Psilocybin is different. As of now, it is a Schedule I substance federally, illegal to prescribe or possess under federal law. But Oregon and Colorado have built state-regulated psilocybin service frameworks that operate legally within those states, and illegally federally. In this model, psilocybin is administered outside the traditional prescribing model, through licensed facilitators rather than physicians writing prescriptions. Other states are moving toward similar frameworks; the map is not static.
MDMA is Schedule I federally with no state-regulated service model equivalent to Oregon's or Colorado's psilocybin programs, following the FDA's 2024 rejection of MDMA-assisted therapy for PTSD. Patients asking about MDMA therapy are almost certainly describing research settings, underground practice, or international clinics, not something you can refer them to domestically through conventional channels.
And then there is everything happening outside medicine altogether: retreats, underground guides, community ceremonies, patients traveling internationally, plant medicines vs synthetics, microdosing vs macrodosing. You won’t be able to recommend any of this by knowing more about it, but you can counsel more safely, because a patient who trusts you enough to disclose this is a patient you can actually help stay safer.
Assisted Therapy: Understanding why psychotherapy is a crucial part of psychedelic-assisted care, helping patients prepare for the experience, navigate what arises during treatment, and integrate insights afterward in ways that support meaningful and lasting change.
In our view, integration is not optional. Altered states can surface powerful emotions, memories, insights, and shifts in perspective, but the experience itself is only part of the therapeutic process. Integration creates the space to make sense of what emerged, translate insight into action, and support changes that can be carried into daily life.
We also believe this work is best supported by a therapist or clinician who is specifically trained to understand altered states of consciousness. That training helps them recognize the unique psychological terrain that can arise before, during, and after psychedelic experiences, and to support patients safely, skillfully, and without imposing meaning onto the experience.
If a patient cannot get access to such a trained clinician, then working with a mental health professional who is willing to navigate the experience alongside them is better than having no one at all.
How to have the conversation
The instinct to change the subject, or to deliver a flat warning and move on, is understandable and unhelpful. A few reframes make this easier in practice.
Ask before you inform. "Tell me what you're considering" gets you more useful information than "here's what you should know," and it tells you immediately how much the patient already understands, which shapes everything you say next.
Separate curiosity from intent. A patient asking what you think about microdosing is in a different conversation than a patient who has already scheduled a retreat. Match your depth of response to where they actually are, not where the question makes you assume they are.
State your scope honestly. "I'm not a psychedelic specialist, but I can help you think through the medical side of this" is a complete, credible sentence. Patients do not expect you to know everything. They expect you not to shut the door.
If you know of medical contraindications relevant to your patient, disclose them. For example: “Before pursuing this experience, I’d recommend speaking with a psychiatrist or clinician with expertise in psychedelic medicine. Your current prescription of X may interact with X, so it’s important to have that reviewed before moving forward.”
Hold the uncertainty out loud if you need to. "The legal landscape here is genuinely inconsistent, and I want to give you accurate information rather than a confident guess" is a better answer than performing certainty you don't have.
Documentation: what to capture and why
You may chart disclosed psychedelic use the way you'd chart any substance use history: what was used, approximate frequency and recency, context, whether clinical, ceremonial, recreational, or underground, and any reported effects relevant to their presenting concerns. Note the counseling you provided and any referrals made or declined, and why.
You may also find the nature of the conversation unrelated to a patient’s clinical concern or chief complaint. Exercise your clinical judgement on whether to chart or not. Always consult your legal advisor if you are uncertain. We recommend Vicente Law Firm (https://vicentellp.com).
Patients might not want this information recorded in their file. Depending on the nature of the inquiry and of the medical consultation, a clinician may be ethically and legally obligated to document clinical findings, recommendations, and even recreational psychedelic use if related to a clinical question or side effect. So you will want to inform your patient of this and exercise both the appropriate judgement and discretion.
And there is also the question of continuity. The next clinician who sees this patient, possibly you in six months or a year, might need to know this conversation happened and what came of it.
When and how to refer
Not every disclosure needs a referral. Plenty of conversations end appropriately with information, resources, and reassurance. Refer when a patient is actively pursuing treatment and needs medical clearance or monitoring, when there's a condition or medication interaction that needs specialist input before they proceed, or when the patient explicitly asks for a referral and you don't have the expertise to evaluate whether it's appropriate.
A referral pathway is only useful if it exists before you need it. If you don't already have a relationship with a ketamine clinic, an integrative psychiatrist, or a state-licensed psilocybin facilitator you trust, that's worth building now, not while a patient is sitting across from you.
It is always best to refer to multiple people to avoid referral liability.
Referring across the state-federal gap
Some of the referrals you'll be asked to make can sit at an uncomfortable legal position: the therapy is licensed and regulated in one state and remains a Schedule I substance federally. Oregon and Colorado's psilocybin service programs are the clearest example. This changes what you say, what you write down, and what you should ask a lawyer before you build a standing referral relationship around it.
The following isn't a substitute for review by a healthcare attorney in your state, particularly before you formalize any referral relationship, sign a collaboration agreement, or accept any form of compensation tied to referrals. Treat this as the list of questions to bring to that conversation, not the answer to them.
What the conflict actually is. Psilocybin services in Oregon and Colorado operate under state license, administered through trained facilitators rather than physicians writing prescriptions. Federally, psilocybin remains Schedule I. The state program does not change federal scheduling; it creates a state-level carve-out for conduct that happens entirely within that state's licensed system. A patient traveling from another state to use it is relying on the law where the service is delivered, not on their home state's law.
Where you, as the referring clinician, actually stand. Making an informational referral, telling a patient a state-licensed program exists and how to find it, is different from prescribing, dispensing, or administering the substance yourself. You are not the one providing the treatment. That distinction is why most clinicians can discuss and refer to these programs without personally holding any license related to psilocybin. It is not a guarantee that no professional or institutional risk exists, which is exactly why this belongs on your attorney's desk rather than assumed away here.
Practical points worth raising with counsel and your compliance or risk management contact:
Keep your own role to information and referral, not direction. Document that you provided information about a program the patient can access legally in that state.
Check your malpractice coverage before this becomes a routine part of your practice. Some carriers have specific exclusions or reporting requirements around psychedelic-adjacent referrals, and finding out after an incident is the wrong time.
If any formal referral relationship involves compensation, a shared marketing arrangement, or a data-sharing agreement with the out-of-state program, have it reviewed for anti-kickback and self-referral exposure the same way you would for any other referral relationship, especially where any patient involved has Medicare or Medicaid coverage.
If the law des not permit it or you are outside of your scope, it is best not to provide the therapy yourself, remotely or otherwise to fill the gap.
Confirm whether your own state medical board or other professional licensing board has issued guidance relevant to psychedelic-related care. A growing number of boards are addressing areas such as ketamine treatment, psilocybin services, off-label care, scope of practice, and professional boundaries, and the regulatory landscape is evolving quickly.
See:
Oregon Medical Board
Washington Medical Commission
Georgia Composite Medical Board
Pennsylvania State Board of Medicine
New Mexico Medical Board
North Carolina Medical Board, though not psychedelic-specific referral guidance
California Medical Board, general referral/scope guidance rather than psychedelic-specific guidance
Language you can use with the patient. The goal is to be factually accurate about what exists and clear about the boundary of your own role, without either endorsing or discouraging what is, for that patient, a legal option in the state where it's offered.
"There's a legal, state-licensed psilocybin program in Oregon and Colorado. I'm not affiliated with it and I can't prescribe or arrange it directly, but I can tell you how it's structured and what to ask if you're considering it."
"I want to be clear about what I can and can't speak to here. I'm not a specialist in this and it isn't legal under federal law, only under specific state programs, so what I can offer is information, not a referral in the way I'd refer you to a cardiologist."
"If you decide to pursue this, I'd want to know so I can keep it in mind for your care afterward, the same way I would with any treatment you got outside this office."
Language to avoid. It is best to avoid writing or saying anything that reads as directing, arranging, or authorizing the treatment on your letterhead or in your professional capacity, phrases like "I am referring you for psilocybin therapy" or "I recommend you proceed with treatment at [program]" read very differently from "the patient inquired about state-licensed psilocybin services; I provided general information and discussed risks and legal status." The second is documentation of informed discussion. You can, however, refer in this way for Ketamine or Spravato. These are legal medicines across the United-States.
A worked example: a Colorado referral from outside Colorado. A patient in your home state, where you are licensed and where psilocybin has no legal service framework, asks you about Colorado's regulated psilocybin program after reading about it online.
What you are not: licensed in Colorado, affiliated with the program, or in any position to administer, supervise, or arrange the protocol yourself, including by telehealth. Colorado's carve-out protects conduct that happens inside its licensed system. It does not extend to you, sitting in a different state, doing any part of the facilitation remotely.
What you can do: tell the patient the program exists, describe how it's structured in plain terms, such as it being a licensed-facilitator model rather than a physician-prescribed one, and point them to where to find current information about it. That is an informational referral. It is not different, in kind, from mentioning a fertility clinic in another state without holding a reproductive endocrinology license there yourself. Make multiple referrals, not just one.
What can go in the chart: "Patient inquired about Colorado's state-licensed psilocybin program. Provided general information about program structure and legal status; discussed [relevant medical history, e.g., medication interactions, contraindications].
Advised the patient to consult programs directly for eligibility and scheduling."
What does not belong in the chart, or in anything you say to the patient: language that reads as directing or authorizing treatment, such as "referring for psilocybin therapy" or "recommend you proceed at [program name]." That phrasing implies clinical direction over a treatment you have no license to direct, and it's the difference between documentation that protects you and documentation that exposes you.
The open question: Has your own state's medical board or other licensing authority issued guidance that could affect referrals to out-of-state psychedelic programs?
Before making these referrals a routine part of practice, clinicians should confirm the rules applicable to their own license and jurisdiction, ideally with qualified legal counsel.
When referrals don’t work out, there is potential liability for negligent referral.
Common Forms of Negligent Referral
• Incompetent Specialist: Referring a patient to a surgeon or specialist whom the provider knew—or should have known—was unqualified, impaired, or had a history of dangerous errors.
• Wrong Specialist: Sending a patient to the incorrect type of specialist for their specific symptoms, which causes a dangerous delay in proper treatment.
• Failure to Refer: Continuing to treat a patient or ignoring complex symptoms that are outside the provider's scope of expertise instead of sending them to an expert.
• Lack of Follow-Up: Failing to track whether the patient saw the specialist or neglecting to review the specialist's findings and treatment plan.
We are living in a digital world
Identifying and Mitigating Patient Safety Risks Associated With Telehealth Referrals: https://www.thedoctors.com/the-doctors-advocate/third-quarter-2024/telehealth-referrals-patient-safety-grants
Where this goes from here
This primer gives you enough to recognize the conversation, respond without either overstating your expertise or shutting the patient down, and know where your responsibility ends and a referral begins.
Building this into how a practice actually operates, staff training, documentation templates, referral relationships, patient-facing language, is a different project, and it's the one we do at Beyond Consulting. If you want to go past the floor, get in touch www.beyondconsulting.life/contact
For all care and strategies specific to women’s health, visit www.galileahealth.com
You can also seek legal council from our partners: Vicente Law Firm
*This article and associated resources are not medical or legal advice.
